The tumor microenvironment creates powerful obstacles for cancer immunotherapy by limiting the expansion of local tumor-specific T lymphocytes, preventing T-cell penetration and the killing of tumor-specific targets. Therefore, therapeutic targeting of the tumor microenvironment combined with immunotherapy is a logical and attractive approach. We have shown that both chemotherapy and treatment targeted to mutated BRAF increased the susceptibility of melanoma cells to the cytotoxic effect of T cells through a dramatic perforin-independent increase in permeability to granzyme B (GrzB) released by activated cytotoxic T cells (CTL). Our data strongly suggested that this effect was mediated via up-regulation of the expression of mannose-6-phosphate receptors (MPR) on the surface of tumor cells while undergoing autophagy. When combined with chemo- or targeted therapy, CTLs raised against specific antigens were able to induce apoptosis in neighboring tumor cells that did not express those antigens, creating a bystander effect. Our preliminary experiments demonstrated that BRAF inhibitors with potent anti-tumor activity against melanoma induced up-regulation of MPR in BFAF mutated melanoma cells, suggesting that they might provide a potent bystander effect with adoptive cell therapy. In the current proposal we will further explore the mechanisms by which targeted and chemotherapeutic agents alter tumor susceptibility to T cell destruction, and propose two clinical trials. In the first trial we will biopsy accessible tumors from patients receiving either a targeted BRAF agent or a chemotherapeutic drug before and after treatment and determine if MPR, markers of autophagy and GrzB are increased on melanoma cells, and when after initiation of treatment increases in these markers can be measured. These findings will then be translated to a phase II trial of the BRAF inhibitor vemurafenib combined with adoptive cell therapy with tumor infiltrating lymphocytes (TIL) and IL-2 after lymphdepletion. This trial will test whether targeted therapy combined with TIL will increase the clinical efficacy of the immunotherapy and result in a higher proportion of patients who do not drop out before they receive their TIL.

Public Health Relevance

Adoptive cell therapy with TIL is a promising therapy for melanoma, but is practical only for a limited cohort of patients with stage IV disease. In this project we propose preclinical experiments and two clinical trials to increase the efficacy of this treatment and decrease the likelihood that patients will drop out prior to receiving their TIL, increasing the applicability of this technology to patients with stage IV melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA168536-01A1
Application #
8556438
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2013-09-20
Project End
2018-07-31
Budget Start
2013-09-20
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$228,065
Indirect Cost
$92,715
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Freeman-Keller, Morganna; Kim, Youngchul; Cronin, Heather et al. (2016) Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 22:886-94
Pilon-Thomas, Shari; Kodumudi, Krithika N; El-Kenawi, Asmaa E et al. (2016) Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res 76:1381-90
Smalley, Keiran S M; Fedorenko, Inna V; Kenchappa, Rajappa S et al. (2016) Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer 139:1195-201
Prieto-Granada, Carlos N; Wiesner, Thomas; Messina, Jane L et al. (2016) Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. Am J Surg Pathol 40:479-89
Emmons, Michael F; Faião-Flores, Fernanda; Smalley, Keiran S M (2016) The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochem Pharmacol 122:1-9
Smalley, Keiran S M; Eroglu, Zeynep; Sondak, Vernon K (2016) Combination Therapies for Melanoma: A New Standard of Care? Am J Clin Dermatol 17:99-105
Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96
Fedorenko, I V; Abel, E V; Koomen, J M et al. (2016) Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene 35:1225-35
Nemoto, Satoshi; Mailloux, Adam W; Kroeger, Jodi et al. (2016) OMIP-031: Immunologic checkpoint expression on murine effector and memory T-cell subsets. Cytometry A 89:427-9
Woan, K V; Lienlaf, M; Perez-Villaroel, P et al. (2015) Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol 9:1447-57

Showing the most recent 10 out of 33 publications